1-(3-(4-bromo-1-methyl-1H-pyrazol-5-yl)phenyl)-3-(4-chlorophenyl)urea

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(3-(4-bromo-1-methyl-1H-pyrazol-5-yl)phenyl)-3-(4-chlorophenyl)urea
• 英文别名: 1-[3-(4-bromo-2-methylpyrazol-3-yl)phenyl]-3-(4-chlorophenyl)urea
• 化学式: C₁₇H₁₄BrClN₄O
• 分子量: 405.7
• InChiKey: MGQBRTUTEMOGLZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  59
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Anti-psychosis combination
  申请人：——

  公开号：US20020156068A1

  公开（公告）日：2002-10-24

  This invention relates to methods of reducing hyperlocomotor activity and stereotypy by administering a composition comprising a modulator of the 5-HT2A receptor with a neuroleptic agent used for treating psychoses, such as Haloperidol. The invention further relates to compositions comprising a modulator of the 5-HT2A receptor with a neuroleptic agent.

  本发明涉及通过施用一种包含5-HT2A受体调节剂与用于治疗精神病的神经安定剂（如氟哌啶醇）的组合物来减少过度运动活动和刻板行为的方法。本发明还涉及由 5-HT2A 受体调节剂和神经安定剂组成的组合物。
• SMALL MOLECULE MODULATORS OF THE 5−HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO
  申请人：Arena Pharmaceuticals, Inc.

  公开号：EP1509505A2

  公开（公告）日：2005-03-02
• [EN] ANTI-PSYCHOSIS COMBINATION<br/>[FR] COMBINAISON ANTI-PSYCHOSE
  申请人：ARENA PHARM INC

  公开号：WO2002076464A1

  公开（公告）日：2002-10-03

  This invention relates to methods of reducing hyperlocomotor activity and stereotypy by administering a composition comprising a modulator of the 5-HT2A receptor with a neuroleptic agent used for treating psychoses, such as Haloperidol. The invention further relates to compositions comprising a modulator of the 5-HT2A receptor with a neuroleptic agent.
• [EN] SMALL MOLECULE MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO<br/>[FR] MODULATEURS A PETITES MOLECULES DU RECEPTEUR DE SEROTONINE 5-HT2A UTILES POUR LA PROPHYLAXIE ET LE TRAITEMENT DE TROUBLES ASSOCIES
  申请人：ARENA PHARM INC

  公开号：WO2003062206A2

  公开（公告）日：2003-07-31

  The present invention relates to certain pyrazole derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Formula (I): Compounds and pharmaceutical compositions thereof are directed to methods useful in the prophylaxis or treatment of reducing platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia and NOS schizophrenia and related disorders. The present invention also relates to the method of prophylaxis or treatment of 5-HT2A serotonin receptor mediated disorders in combination with a dopamine D2 receptor antagonist such as haloperidol, administered separately or together.
• [EN] PROCESS OF MAKING PHENYLPYRAZOLES USEFUL AS SELECTIVE 5HT2A MODULATORS AND INTERMEDIATES THEREOF<br/>[FR] PROCEDE DE FABRICATION DE PHENYLPYRAZOLES UTILES EN TANT QUE MODULATEURS SELECTIFS DE 5HT2A ET LEURS INTERMEDIAIRES
  申请人：ARENA PHARM INC

  公开号：WO2004028450A2

  公开（公告）日：2004-04-08

  The present invention relates to a process for making certain selective 5HT2A modulators of Formula (I) and the intermediates thereof: Formula (I) wherein Rl-R7 are described. Compounds of Formula (I) are useful in the prophylaxis or treatment of 5HT2A mediated diseases, such as, 5HT2A mediated platelet aggregation, asthma, agitation, degenerative diseases of the CNS and the like.